BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Phase 2 clinical trial evaluating intranasal foralumab in patients with amyotrophic lateral sclerosis (ALS) has been accepted for inclusion in the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS at Mass General Brigham. The study, supported by a grant from the ALS Association, wil ...

Core Viewpoint - Tiziana Life Sciences is participating in the Jefferies London Healthcare Conference to present its innovative pipeline and recent clinical milestones, particularly focusing on its lead candidate, intranasal foralumab, which targets neurodegenerative diseases [1][2][3]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies, specifically intranasal foralumab, a fully human anti-CD3 monoclonal antibody [6]. Product Details - Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development, administered intranasally for conditions such as non-active secondary progressive multiple sclerosis (SPMS), Alzheimer's disease (AD), multiple system atrophy (MSA), and amyotrophic lateral sclerosis (ALS) [2][5]. - In an open-label intermediate sized Expanded Access Program, 14 patients with non-active SPMS have shown either improvement or stability of disease within 6 months [5]. Clinical Trials - Foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial for non-active SPMS [5]. Conference Participation - The Jefferies London Healthcare Conference will take place on November 19, 2025, where Tiziana's management will present and be available for one-on-one meetings [4].

Company Overview - Tiziana Life Sciences Ltd. (TLSA) is a biotech company focused on developing Foralumab, an anti-CD3 monoclonal antibody designed for intranasal delivery to modulate immune responses in the brain [1]. Product Development - Foralumab aims to induce regulatory T cells (Tregs) and calm immune responses, potentially offering therapeutic benefits in various neurological conditions [1].

Group 1 - Tiziana Life Sciences Ltd. (TLSA) is a biotech company focused on developing Foralumab, an anti-CD3 monoclonal antibody designed for intranasal delivery to modulate immune responses in the brain [1] - Foralumab aims to induce regulatory T cells (Tregs) to help calm immune responses [1]

Core Viewpoint - Tiziana Life Sciences is advancing its second asset, TZLS-501, a fully human anti-IL-6 receptor monoclonal antibody, amidst increased industry activity in the IL-6 pathway, highlighted by Novartis' acquisition of Tourmaline Bio for approximately $1.4 billion [1][3]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies, particularly intranasal administration [9][10]. Product Development - TZLS-501 targets both membrane-bound and soluble forms of IL-6R, potentially offering therapeutic advantages in managing diseases characterized by excessive IL-6 signaling, such as rheumatoid arthritis, acute respiratory distress syndrome, and various cancers [2][4]. - The company plans to pursue non-dilutive funding strategies for the development of TZLS-501 while continuing to advance its lead program, intranasal foralumab [1][3]. Market Context - The recent acquisition by Novartis underscores the growing importance of IL-6 therapeutics, positioning Tiziana to capitalize on this trend with the development of TZLS-501 [3][5]. - The dual mechanism of action of TZLS-501, which inhibits IL-6R signaling and reduces circulating IL-6 cytokines, is seen as a significant advancement in treating acute and chronic inflammatory conditions [2][6]. Clinical Programs - Foralumab, Tiziana's lead candidate, is currently being studied in clinical trials for its efficacy in treating non-active secondary progressive multiple sclerosis, with positive outcomes reported in initial patient dosing [7][8].

Group 1 - The article discusses Tiziana Life Sciences (NASDAQ: TLSA) and its ongoing drug development efforts, particularly focusing on the Foralumab drug and its additional Expanded Access Program (EAP) enrollment [2] - The author is affiliated with Biotech Analysis Central, which provides extensive analysis and resources for healthcare investors, including a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks [2] - The service offered by Biotech Analysis Central is priced at $49 per month, with a yearly plan available at a discounted rate of $399, representing a 33.50% discount [1] Group 2 - The article does not provide specific financial data or performance metrics related to Tiziana Life Sciences or its products [4] - There are no disclosed positions or plans to initiate positions in the companies mentioned, indicating a neutral stance from the author [3]

Core Insights - Tiziana Life Sciences Ltd. is focused on developing immunomodulation therapies, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody [1][4] - The Executive Chairman, Mr. Gabriele Cerrone, has increased his stake in the company by purchasing 15,000 shares at $1.55 each, now holding 43,252,143 shares, which constitutes 37.02% of the total issued share capital [1] Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company that aims to develop innovative therapies using advanced drug delivery technologies, particularly focusing on alternative routes for immunotherapy [4] - The company’s lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, showing a favorable safety profile and clinical response in previous studies [4] Product Development - Foralumab has been administered to 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) in an open-label Expanded Access Program, with all patients showing either improvement or stability of disease within 6 months [2] - A Phase 2a trial for intranasal foralumab began screening patients in November 2023, focusing on its efficacy in treating non-active secondary progressive multiple sclerosis [3] Innovation and Technology - Tiziana's nasal delivery approach is expected to enhance both efficacy and safety compared to traditional intravenous delivery methods, potentially leading to broader applications in immunotherapy [4] - The company has patented its technology for alternative routes of immunotherapy, with several applications pending, indicating a strong pipeline for future developments [4]